RHRobert Harrington

Robert Harrington

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert Harrington has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The presence of myositis specific and myositis associated antibodies does not alter prognosis in IPF

    by Robert Harrington, Richard Conway, Ruairi Fahy

    Background: Myositis specific antibodies (MSA) and myositis associated antibodies (MAA) can be detected in pulmonary involvement in systemic autoimmune rheumatic diseases. The prognostic effect of these antibodies in IPF however remains unclear. Methods: This is a monocentric 7-year retrospective cohort study of IPF patients from 2016 to 2022. IPF patients with MSA/MAA antibodies were age and sex matched 1:1 to IPF patients without antibodies. The 2 groups were analysed by PFTs, all-cause mortality, and presence of malignancy. Results: 17/109 (15.6%) IPF patients (12 male, 5 female) with MSA/MAA antibodies were identified. Anti-Mi2-β was detected in 6/17 (35.3%). The mean age at diagnosis was 71.9 (std +/- 8.6) and the mean disease duration was 3.79 (std +/- 2.81) years. There were no differences between groups in disease duration, smoking history, or prior malignancy. There was no difference in baseline FVC between the MSA/MAA group and the antibody negative group; 90.68% vs. 89.86% (p = 0.911). The baseline DLCO was also the same; 60.20% vs. 58.49% (p = 0.810). There was no difference in the decline in FVC predicted per year between the MSA/MAA group and the antibody negative group; -2.09% vs. -2.24% (p = 0.965). There was also no difference in the decline in DLCO per year either; -5.65% vs. -6.24% (p = 0.866). There was no difference in all-cause mortality with 5 deaths in the MSA/MAA group and 7 in the antibody negative group (p = 0.720). Conclusion: MSA/MAA antibodies do not alter disease trajectory in terms of lung function or all-cause mortality in IPF. Larger longitudinal studies are needed to determine if MSA/MAA antibodies in IPF are prognostically important or merely epiphenomena.

  • Anti-Ro52 positivity is associated with poorer lung function at diagnosis in CTD-ILD and IIM-ILD

    by Robert Harrington, Richard Conway, Ruairi Fahy

    Background: Recent cohort studies suggest an association with anti-Ro52 antibodies and more progressive ILD in CTD-ILD and IIM-ILD. This study investigates the significance of anti-Ro52 positivity in an Irish cohort of patients. Methods: This is a monocentric 7-year retrospective cohort study of CTD-ILD and IIM-ILD patients. 781 extended myositis panel results were screened from 2016 to 2022 to identify a suitable cohort. PFT data was analysed to explore the significance of anti-Ro52 positivity. Results: 41 CTD-ILD and IIM-ILD patients (19 male, 22 female) were included. The mean age was 66.7 (std +/- 13.2) and the mean disease duration was 4.4 years (std +/- 2.6). 14/41 patients were anti-Ro52+. The anti-Ro52+ cohort had a significantly lower baseline DLCO at diagnosis; 41.70% vs. 55.41% (p = 0.009). Baseline FVC predicted was numerically lower in the anti-Ro52+ cohort but did not reach statistical significance; 75.78% vs. 92.83% (p = 0.083). After standard of care treatment, the anti-Ro52+ cohort had poorer FVCs; 72.16% vs. 97.06% (p = 0.028). There was no difference in all-cause mortality with 3 deaths among the anti-Ro52+ cohort and 4 among the anti-Ro52- cohort (p = 0.673). No associations between anti-Ro52 status and smoking, malignancy or ILD pattern on CT were found. Patients under 65 presented with lower baseline FVC compared with those over 65 irrespective of anti-Ro52 status; 75.45% vs. 95.60% (p = 0.026). Conclusion: Anti-Ro52 antibodies are asssociated with a lower baseline DLCO in CTD-ILD and IIM-ILD patients. Patients under 65 also presented with a more markedly reduced FVC than more elderly patients, perhaps reflecting the fulminant nature of disease onset in this demographic.

  • Meta-analysis of rituximab treatment of systemic sclerosis related interstitial lung disease

    by Robert Harrington, Richard Conway, Ruairi Fahy

    Background: ILD is now the leading cause of mortality in systemic sclerosis (SSc) with a 10-year mortality of 40%. Clinical trials with cyclophosphamide (CYC), mycophenolic acid and tocilizumab in SSc-ILD have all shown a degree of efficacy but there are no well powered RCTs for rituximab (RTX) treatment of SSc-ILD. Methods: A comprehensive search strategy using PubMed, Embase and the Cochrane Library was conducted to identify studies of RTX treatment of SSc-ILD. The suitability of 46 studies were reviewed. Only trials with both CT evidence of ILD and a mean baseline FVC of less than 80% predicted were included. Cochrane’s RevMan software was used to produce the forest plots. Results: 17 studies were included for analysis; 4 RCTs, 5 prospective, and 8 retrospective. Meta-analysis of 7 studies produced a forest plot suggesting an improvement in FVC at 6 months. Similarly, the inclusion of 12 studies produced a forest plot demonstrating similar improvement in FVC at 12 months. 3 RCTs comparing RTX and CYC were also analysed. The forest plot produced suggests a greater beneficial effect with RTX on FVC at 6 months. erj;64/suppl_68/PA694/F1 F1 F1 Conclusion: This meta-analysis suggests that RTX treatment of SSc-ILD results in improved lung function rather than just stabilisation. The forest plot of the 3 RCTs comparing RTX and CYC is in favour of RTX. These results are reassuring and suggest RTX may be opted for particularly if CYC toxicity is a concern.

  • Open Access

    A Novel Pool of Microparticle Cholesterol Is Elevated in Rheumatoid Arthritis but Not in Systemic Lupus Erythematosus Patients

    by Shuaishuai Hu, Brenton L. Cavanagh, Robert Harrington, Muddassar Ahmad, Grainne Kearns, Steve Meaney, Claire Wynne

    Microparticles are sub-micron, membrane-bound particles released from virtually all cells and which are present in the circulation. In several autoimmune disorders their amount and composition in the circulation is altered. Microparticle surface protein expression has been explored as a differentiating tool in autoimmune disorders where the clinical pictures can overlap. Here, we examine the utility of a novel lipid-based marker—microparticle cholesterol, present in all microparticles regardless of cellular origin—to distinguish between rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). We first isolated a series of microparticle containing lipoprotein deficient fractions from patient and control plasma. There were no significant differences in the size, structure or protein content of microparticles isolated from each group. Compared to controls, both patient groups contained significantly greater amounts of platelet and endothelial cell-derived microparticles. The cholesterol content of microparticle fractions isolated from RA patients was significantly greater than those from either SLE patients or healthy controls. Our data indicate that circulating non-lipoprotein microparticle cholesterol, which may account for 1–2% of measured cholesterol in patient samples, may represent a novel differentiator of disease, which is independent of cellular origin.